Progress in treatment of follicular lymphoma
10.3760/cma.j.issn.1009-9921.2017.01.008
- VernacularTitle:滤泡淋巴瘤治疗研究进展
- Author:
Yingying YUAN
;
Jianyong LI
;
Wei XU
- Keywords:
Follicular lymphoma;
Treatment progression;
American Society of Hematology Annual Meeting
- From:
Journal of Leukemia & Lymphoma
2017;26(1):21-23,27
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma (iNHL), which origins from follicle germinal center. Multiple researches reported the latest development about treatment of FL in the 58th American Society of Hematology (ASH) Annual Meeting. The outcomes of clinical trials in which GAl01 combined with chemotherapy and bendamustine in combination with 90Y-ibritumomab tiuxetan for the advanced stage FL were exciting. Relapsed/refractory FL patients who receive tandem autologous followed by nonmyeloablative allogeneic transplantation could acquire preferable remissions. With the emerging of novel drugs including inhibitor of bcl-2 or PI3K and antibody drug conjugate, more and more improvements of efficacy and remission were made in the treatment of relapsed/refractory FL therapy and remission.
